Arun K Ghosh

List of Publications by Year in Descending Order

374 papers	15,989 citations	66 h-index	108 g-index
413 ext. papers	17,691 ext. citations	5.1 avg, IF	6.8 L-index

#	Paper	IF	Citations
374	Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors .. *Antimicrobial Agents and Chemotherapy*, **2022**, AAC0171521	5.9	2
373	U2 snRNA structure is influenced by SF3A and SF3B proteins but not by SF3B inhibitors. *PLoS ONE*, **2021**, 16, e0258551	3.7	
372	Enantioselective Total Synthesis of (+)-EBC-23, a Potent Anticancer Agent from the Australian Rainforest. *Journal of Organic Chemistry*, **2021**, 86, 6351-6360	4.2	3
371	Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. *Journal of Natural Products*, **2021**, 84, 1681-1706	4.9	2
370	Highly Diastereoselective Intramolecular Asymmetric Oxidopyrylium-olefin [5 + 2] Cycloaddition and Synthesis of 8-Oxabicyclo[3.2.1]oct-3-enone Containing Ring Systems. *Journal of Organic Chemistry*, **2021**, 86, 8127-8142	4.2	2
369	The Chiron Approach to (3,3,6)-Hexahydrofuro[2,3-]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir. *Journal of Organic Chemistry*, **2021**, 86, 1216-1222	4.2	2
368	Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents. *Tetrahedron Letters*, **2021**, 63,	2	3
367	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. *Nature Communications*, **2021**, 12, 668	17.4	55
366	Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing. *ACS Chemical Biology*, **2021**, 16, 520-528	4.9	0
365	A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors. *ACS Chemical Neuroscience*, **2021**, 12, 581-588	5.7	0
364	Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors. *Nature Communications*, **2021**, 12, 4491	17.4	3
363	Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR. *Biochemical and Biophysical Research Communications* , **2021**, 566, 30-35	3.4	2
362	Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 14702-14714	8.3	17
361	Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors. *Molecules*, **2021**, 26,	4.8	2
360	Design and synthesis of herboxidiene derivatives that potently inhibit splicing. *Organic and Biomolecular Chemistry*, **2021**, 19, 1365-1377	3.9	1
359	Copper-Catalyzed Stille Cross-Coupling Reaction and Application in the Synthesis of the Spliceostatin Core Structure. *Journal of Organic Chemistry*, **2020**, 85, 8111-8120	4.2	6
358	Fluorescent Probes for Monitoring Serine Ubiquitination. *Biochemistry*, **2020**, 59, 1309-1313	3.2	4

357	Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. *Scientific Reports*, **2020**, 10, 10664	4.9	2
356	Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1965-1972	4.3	3
355	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2020**, 63, 4867-4879	8.3	8
354	Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. *ChemMedChem*, **2020**, 15, 907-932	3.7	155
353	Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. *Journal of Medicinal Chemistry* , **2020**, 63, 2751-2788	8.3	73
352	Lewis Acid-Catalyzed Vinyl Acetal Rearrangement of 4,5-Dihydro-1,3-dioxepines: Stereoselective Synthesis of and 2,3-Disubstituted Tetrahydrofurans. *Journal of Organic Chemistry*, **2020**, 85, 10399-10412	4.2	2
351	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. *MBio*, **2020**, 11,	7.8	34
350	Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20. *Biochemical and Biophysical Research Communications*, **2019**, 519, 61-66	3.4	9
349	Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors. *Biochemistry*, **2019**, 58, 4424-4435	3.2	7
348	Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
347	Novel Protease Inhibitors Containing C-5-Modified -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	8
346	Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I. *Biochemical and Biophysical Research Communications*, **2019**, 514, 974-978	3.4	9
345	Enantioselective Total Synthesis of (+)-Monocerin, a Dihydroisocoumarin Derivative with Potent Antimalarial Properties. *Journal of Organic Chemistry*, **2019**, 84, 6191-6198	4.2	5
344	Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s. *Scientific Reports*, **2019**, 9, 4828	4.9	6
343	Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	7
342	Enantioselective Total Syntheses of (+)-Fendleridine and (+)-Acetylaspidoalbidine. *Journal of Organic Chemistry*, **2019**, 84, 5167-5175	4.2	6
341	Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 2565-2570	2.9	6
340	A Photochemical Route to Optically Active Hexahydro-4-furopyranol, a High-Affinity P2 Ligand for HIV-1 Protease Inhibitors. *Journal of Organic Chemistry*, **2019**, 84, 9801-9805	4.2	4

339	Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies. *ChemMedChem*, **2019**, 14, 1863-1872	3.7	9
338	A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. *Global Health & Medicine*, **2019**, 1, 36-48	2.4	2
337	Asymmetric Diels-Alder reaction of 3-(acyloxy) acryloyl oxazolidinones: optically active synthesis of a high-affinity ligand for potent HIV-1 protease inhibitors. *RSC Advances*, **2019**, 9, 41755-41763	3.7	1
336	Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies. *ChemMedChem*, **2019** , 14, 545-560	3.7	4
335	Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants. *ChemMedChem*, **2018**, 13, 803-815	3.7	23
334	GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	6
333	The Curtius rearrangement: mechanistic insight and recent applications in natural product syntheses. *Organic and Biomolecular Chemistry*, **2018**, 16, 2006-2027	3.9	49
332	Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. *MBio*, **2018**, 9,	7.8	23
331	Enantioselective Synthesis of Thailanstatin A Methyl Ester and Evaluation of in Vitro Splicing Inhibition. *Journal of Organic Chemistry*, **2018**, 83, 5187-5198	4.2	18
330	Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2074-2079	2.9	9
329	Enantioselective total synthesis of decytospolide A and decytospolide B using an Achmatowicz reaction. *Organic and Biomolecular Chemistry*, **2018**, 16, 5979-5986	3.9	3
328	Differentiating Isomeric Deprotonated Glucuronide Drug Metabolites via Ion/Molecule Reactions in Tandem Mass Spectrometry. *Analytical Chemistry*, **2018**, 90, 9426-9433	7.8	10
327	Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors. *Asian Journal of Organic Chemistry*, **2018**, 7, 1448-1466	3	2
326	Enantioselective Synthesis of Spliceostatin G and Evaluation of Bioactivity of Spliceostatin G and Its Methyl Ester. *Organic Letters*, **2018**, 20, 96-99	6.2	12
325	Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease. *ACS Omega*, **2018**, 3, 12132-12140	3.9	12
324	Enantioselective Synthesis of a Cyclopropane Derivative of Spliceostatin A and Evaluation of Bioactivity. *Organic Letters*, **2018**, 20, 7293-7297	6.2	11
323	Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies. *Journal of Medicinal Chemistry*, **2018**, 61, 9722-9737	8.3	17
322	The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry. *ChemMedChem*, **2018**, 13, 2351-2373	3.7	42

321	Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands. *European Journal of Medicinal Chemistry*, **2018**, 160, 171-182	6.8	3
320	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. *Journal of Medicinal Chemistry*, **2018**, 61, 4561-4577	8.3	19
319	Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2605-2610	2.9	2
318	Total syntheses of both enantiomers of amphirionin 4: A chemoenzymatic based strategy for functionalized tetrahydrofurans. *Tetrahedron*, **2017**, 73, 1820-1830	2.4	7
317	Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 5114-5127	3.4	12
316	Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2432-2438	2.9	12
315	Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. *Journal of Medicinal Chemistry*, **2017**, 60, 4267-4278	8.3	47
314	GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. *Scientific Reports*, **2017**, 7, 12235	4.9	10
313	Highly Stereoselective Asymmetric Aldol Routes to -Butyl-2-(3,5-difluorophenyl)-1-oxiran-2-yl)ethyl)carbamates: Building Blocks for Novel Protease Inhibitors. *Tetrahedron Letters*, **2017**, 58, 4062-4065	2	4
312	Lewis Acid Mediated Cyclizations: Diastereoselective Synthesis of Six- to Eight-Membered Substituted Cyclic Ethers. *Synthesis*, **2017**, 49, 4229-4246	2.9	7
311	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4925-4931	2.9	5
310	An enantioselective enzymatic desymmetrization route to hexahydro-4-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors. *Tetrahedron Letters*, **2017**, 58, 3230-3233	2	5
309	Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir. *ChemMedChem*, **2017**, 12, 1942-1952	3.7	3
308	A fission yeast cell-based system for multidrug resistant HIV-1 proteases. *Cell and Bioscience*, **2017**, 7, 5	9.8	4
307	Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development. *ACS Infectious Diseases*, **2017**, 3, 54-61	5.5	21
306	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. *ELife*, **2017**, 6,	8.9	31
305	HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. *Medical Research Archives*, **2017**, 5,	2.1	6
304	Enantioselective Syntheses of (-)-Alloyohimbane and (-)-Yohimbane by an Efficient Enzymatic Desymmetrization Process. *European Journal of Organic Chemistry*, **2016**, 2016, 6001-6009	3.2	12

303	Achmatowicz Reaction and its Application in the Syntheses of Bioactive Molecules. *RSC Advances*, **2016**, 6, 111564-111598	3.7	49
302	Enantioselective total synthesis and structural assignment of callyspongiolide. *Organic and Biomolecular Chemistry*, **2016**, 14, 11357-11370	3.9	13
301	Design, synthesis and in vitro splicing inhibition of desmethyl and carba-derivatives of herboxidiene. *Organic and Biomolecular Chemistry*, **2016**, 14, 5263-71	3.9	13
300	Enantioselective Synthesis of Both Epimers at C-21 in the Proposed Structure of Cytotoxic Macrolide Callyspongiolide. *Organic Letters*, **2016**, 18, 3274-7	6.2	17
299	Stereoselective Synthesis of Substituted Oxocene Cores by Lewis Acid Promoted Cyclization. *Organic Letters*, **2016**, 18, 396-9	6.2	10
298	Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. *Journal of Medicinal Chemistry*, **2016**, 59, 5172-208	8.3	231
297	Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs. *Journal of Immunology*, **2016**, 196, 3608-17	5.3	18
296	Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes. *Chemical Science*, **2016**, 7, 3117-3122	9.4	11
295	Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. *Rna*, **2016**, 22, 350-9	5.8	64
294	Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation. *Journal of Medicinal Chemistry* , **2016**, 59, 6826-37	8.3	11
293	Anharmonic modeling of the conformation-specific IR spectra of ethyl, n-propyl, and n-butylbenzene. *Journal of Chemical Physics*, **2016**, 144, 224310	3.9	23
292	The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer's Disease. *Topics in Medicinal Chemistry*, **2016**, 27-85	0.4	14
291	An enantioselective synthesis of the C3-C21 segment of the macrolide immunosuppressive agent FR252921. *Tetrahedron Letters*, **2016**, 57, 2884-2887	2	3
290	Enantioselective Total Synthesis of (+)-Amphirionin-4. *Organic Letters*, **2016**, 18, 2296-9	6.2	13
289	A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7046-7059	5.9	10
288	Structure-based design, synthesis and biological evaluation of novel β-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand. *Bioorganic and Medicinal Chemistry Letters* , **2015**, 25, 668-72	2.9	17
287	Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1292-6	2.9	16
286	A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2625-35	5.9	9

285	Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4903-4909	2.9	19
284	Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies. *Journal of Medicinal Chemistry*, **2015**, 58, 5334-43	8.3	17
283	Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization. *Tetrahedron Letters*, **2015**, 56, 3314-3317	2	6
282	Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1895-904	5.9	24
281	Characterization of a Drosophila ortholog of the Cdc7 kinase: a role for Cdc7 in endoreplication independent of Chiffon. *Journal of Biological Chemistry*, **2015**, 290, 1332-47	5.4	8
280	Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. *ACS Chemical Biology*, **2015**, 10, 1456-65	4.9	75
279	Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. *Journal of Biological Chemistry*, **2015**, 290, 19403-22	5.4	85
278	X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5072-7	2.9	18
277	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. *Organic and Biomolecular Chemistry*, **2015**, 13, 11607-21	3.9	10
276	Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies. *Journal of Medicinal Chemistry*, **2015**, 58, 6994-7006	8.3	12
275	Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation. *ChemMedChem*, **2015**, 10, 107-15	3.7	18
274	C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. *Journal of Virology*, **2015**, 90, 2180-94	6.6	13
273	HIV-1 Protease Inhibitors for the Treatment of HIV Infection and AIDS: Design of Saquinavir, Indinavir, and Darunavir **2015**, 237-270		2
272	Secretase Inhibitors for the Treatment of Alzheimer's Disease: Preclinical and Clinical Inhibitors **2015**, 421-447		
271	From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design **2015**, 1-18		
270	Development of Direct Thrombin Inhibitor, Dabigatran Etexilate, as an Anticoagulant Drug **2015**, 337-354		1
269	Design of Inhibitors of Aspartic Acid Proteases **2015**, 19-66		
268	Design of Cysteine Protease Inhibitors **2015**, 131-142		

267	Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease. *ChemMedChem*, **2015**, 10, 1463-6	3.7	17
266	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. *Marine Drugs*, **2015**, 13, 3625-39	6	11
265	Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20. *Journal of Medicinal Chemistry*, **2015**, 58, 5088-95	8.3	8
264	Organic carbamates in drug design and medicinal chemistry. *Journal of Medicinal Chemistry*, **2015**, 58, 2895-940	8.3	346
263	Platensimycin and Platencin. *Methods and Principles in Medicinal Chemistry*, **2014**, 271-300	0.4	2
262	Total synthesis of GEX1Q1, assignment of C-5 stereoconfiguration and evaluation of spliceosome inhibitory activity. *Organic Letters*, **2014**, 16, 3154-7	6.2	19
261	Enantioselective total syntheses of FR901464 and spliceostatin A and evaluation of splicing activity of key derivatives. *Journal of Organic Chemistry*, **2014**, 79, 5697-709	4.2	32
260	An Enantioselective Synthesis of a MEM-Protected Aetheramide A Derivative. *Tetrahedron Letters*, **2014**, 55, 5191-5194	2	10
259	Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands. *Organic and Biomolecular Chemistry*, **2014**, 12, 6842-54	3.9	16
258	Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12234-9	11.5	44
257	Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance. *Journal of Virology*, **2014**, 88, 11886-98	6.6	61
256	BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. *Chemical Society Reviews*, **2014**, 43, 6765-813	58.5	232
255	A convergent synthesis of carbocyclic sinefungin and its C5 epimer. *European Journal of Organic Chemistry*, **2014**, 2014, 6761-6768	3.2	6
254	An intramolecular cascade cyclization of 2-aryl indoles: efficient methods for the construction of 2,3-functionalized indolines and 3-indolinones. *Organic and Biomolecular Chemistry*, **2014**, 12, 3567-71	3.9	10
253	FeCl-Catalyzed Tandem Prins and Friedel-Crafts Cyclization: A Highly Diastereoselective Route to Polycyclic Ring Structures. *Tetrahedron Letters*, **2014**, 55, 4251-4254	2	15
252	**2014**,		20
251	A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. *MBio*, **2014**, 5, e00047-14	7.8	47
250	Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors. *Xenobiotica*, **2014**, 44, 404-16	2	5

249	Enantioselective synthesis of spliceostatin E and evaluation of biological activity. *Organic Letters*, **2014**, 16, 6200-3	6.2	15
248	A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 3679-88	5.9	14
247	Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. *Journal of Biological Chemistry*, **2014**, 289, 1938-47	5.4	54
246	Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2013**, 56, 6792-802	8.3	37
245	Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. *Antiviral Research*, **2013**, 97, 232-9	10.8	44
244	Enantioselective syntheses of FR901464 and spliceostatin A: potent inhibitors of spliceosome. *Organic Letters*, **2013**, 15, 5088-91	6.2	38
243	Design of the anti-HIV protease inhibitor darunavir **2013**, 355-384		18
242	Enantioselective Synthesis of Spiro[cyclohexane-1,3'-indolin]-2'-ones Containing Multiple Stereocenters via Organocatalytic Michael/Aldol Cascade Reactions. *Tetrahedron Letters*, **2013**, 54, 2311-2314	2	22
241	Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran. *Journal of Medicinal Chemistry*, **2013**, 56, 4017-27	8.3	29
240	Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease. *Journal of Medicinal Chemistry*, **2013**, 56, 1074-83	8.3	24
239	Bifunctional cinchona alkaloid-squaramide-catalyzed highly enantioselective aza-Michael addition of indolines to □,□unsaturated ketones. *Tetrahedron Letters*, **2013**, 54, 3500-3502	2	16
238	Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design. *Journal of Medicinal Chemistry*, **2013**, 56, 5631-5	8.3	51
237	Enantioselective total synthesis of macrolide (+)-neopeltolide. *Organic and Biomolecular Chemistry*, **2013**, 11, 7768-77	3.9	23
236	GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 6110-21	5.9	20
235	P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 4920-7	5.9	28
234	GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2036-46	5.9	21
233	Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications. *ChemMedChem*, **2013**, 8, 1361-72	3.7	16
232	S-adenosyl-homocysteine is a weakly bound inhibitor for a flaviviral methyltransferase. *PLoS ONE*, **2013**, 8, e76900	3.7	11

231	The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1787-807	3	33
230	Metabolism-Directed Structure Optimization of Benzimidazole-Based F. Tularensis Enoyl-Reductase (FabI) Inhibitors. *FASEB Journal*, **2013**, 27, 664.3	0.9	
229	Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2308-11	2.9	17
228	Synthesis of Functionalized 4-Methylenetetrahydropyrans by Oxidative Activation of Cinnamyl or Benzyl Ethers. *Tetrahedron Letters*, **2012**, 53, 2568-2570	2	7
227	A Tandem Olefin Migration and Prins Cyclization Using Cu(OTf)(2)-Bisphosphine Complexes: An Improved Synthesis of Functionalized Tetrahydropyrans. *Tetrahedron Letters*, **2012**, 53, 3699-3702	2	12
226	Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV. *Angewandte Chemie - International Edition*, **2012**, 51, 1778-802	16.4	109
225	Lasonolide A, a potent and reversible inducer of chromosome condensation. *Cell Cycle*, **2012**, 11, 4424-35	4.7	22
224	Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring. *Journal of Medicinal Chemistry*, **2012**, 55, 3387-97	8.3	11
223	Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor. *Organic Letters*, **2012**, 14, 4730-3	6.2	45
222	Stereoselective synthesis of both tetrahydropyran rings of the antitumor macrolide, (-)-lasonolide A. *Journal of Organic Chemistry*, **2012**, 77, 2559-65	4.2	13
221	Structure-based design, synthesis, and biological evaluation of dihydroquinazoline-derived potent β-secretase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5460-5	2.9	16
220	Structure-based design of highly selective β-secretase inhibitors: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. *Journal of Medicinal Chemistry*, **2012**, 55, 9195-207	8.3	30
219	Enantioselective total synthesis of (+)-lithospermic acid. *Organic Letters*, **2012**, 14, 5046-9	6.2	34
218	TiCl4-promoted tandem carbonyl or imine addition and Friedel-Crafts cyclization: synthesis of benzo-fused oxabicyclooctanes and nonanes. *Organic Letters*, **2012**, 14, 2002-5	6.2	11
217	A stereoselective synthesis of (-)-viridiofungin A utilizing a TiCl(4)-promoted asymmetric multicomponent reaction. *Organic Letters*, **2012**, 14, 510-2	6.2	12
216	Total Synthesis of Potent Antitumor Macrolide, (-)-Zampanolide: An Oxidative Intramolecular Cyclization-Based Strategy. *European Journal of Organic Chemistry*, **2012**, 2012, 4130-4139	3.2	29
215	Verstärkung der Bindung an das Proteinrückgrat – ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV. *Angewandte Chemie*, **2012**, 124, 1812-1838	3.6	8
214	Developing β-secretase inhibitors for treatment of Alzheimer's disease. *Journal of Neurochemistry*, **2012**, 120 Suppl 1, 71-83	6	205

213	Diastereoselective Synthesis of Substituted Tetrahydropyrans by Copper(II)-Bisphosphine-Catalyzed Olefin Migration and Prins Cyclization. *Synthesis*, **2012**, 44, 3579-3589	2.9	6
212	Introduction to the Aspartic Proteinase Family. *Methods and Principles in Medicinal Chemistry*, **2011**, 1-21	0.4	1
211	Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. *Future Medicinal Chemistry*, **2011**, 3, 1181-97	4.1	34
210	HIV-1 Protease: Role in Viral Replication, Protein□ligand X-Ray Crystal Structures and Inhibitor Design. *Methods and Principles in Medicinal Chemistry*, **2011**, 107-137	0.4	1
209	First-Generation HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. *Methods and Principles in Medicinal Chemistry*, **2011**, 139-168	0.4	2
208	Second-Generation Approved HIV Protease Inhibitors for the Treatment of HIV/AIDS. *Methods and Principles in Medicinal Chemistry*, **2011**, 169-204	0.4	2
207	Darunavir, a New PI with Dual Mechanism: From a Novel Drug Design Concept to New Hope against Drug-Resistant HIV. *Methods and Principles in Medicinal Chemistry*, **2011**, 205-243	0.4	4
206	Development of HIV-1 Protease Inhibitors, Antiretroviral Resistance, and Current Challenges of HIV/AIDS Management. *Methods and Principles in Medicinal Chemistry*, **2011**, 245-262	0.4	
205	Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension. *Methods and Principles in Medicinal Chemistry*, **2011**, 263-296	0.4	1
204	Evolution of Diverse Classes of Renin Inhibitors through the Years. *Methods and Principles in Medicinal Chemistry*, **2011**, 297-324	0.4	3
203	□Secretase: An Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 325-351	0.4	
202	□Secretase Inhibition: An Overview of Development of Inhibitors for the Treatment of Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 353-390	0.4	
201	BACE: A (Almost) Perfect Target for Staving off Alzheimer's Disease. *Methods and Principles in Medicinal Chemistry*, **2011**, 391-412	0.4	1
200	The Discovery of □Secretase and Development toward a Clinical Inhibitor for AD: An Exciting Academic Collaboration. *Methods and Principles in Medicinal Chemistry*, **2011**, 413-440	0.4	
199	Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution. *Methods and Principles in Medicinal Chemistry*, **2011**, 441-479	0.4	1
198	Nonpeptide BACE1 Inhibitors: Design and Synthesis. *Methods and Principles in Medicinal Chemistry*, **2011**, 481-509	0.4	1
197	The Plasmepsin Family as Antimalarial Drug Targets. *Methods and Principles in Medicinal Chemistry*, **2011**, 511-547	0.4	
196	Plasmepsins Inhibitors as Potential Drugs against Malaria: Starving the Parasite. *Methods and Principles in Medicinal Chemistry*, **2011**, 549-571	0.4	

195	Fungal Aspartic Proteases as Possible Therapeutic Targets. *Methods and Principles in Medicinal Chemistry*, **2011**, 573-606	0.4	1
194	Structure-Based Drug Design Strategies for Inhibition of Aspartic Proteinases. *Methods and Principles in Medicinal Chemistry*, **2011**, 71-105	0.4	1
193	Human Aspartic Proteinases. *Methods and Principles in Medicinal Chemistry*, **2011**, 43-70	0.4	
192	Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. *FASEB Journal*, **2011**, 25, 775-84	0.9	93
191	Aspartic Proteases: Structure, Function, and Inhibition. *Methods and Principles in Medicinal Chemistry*, **2011**, 23-41	0.4	1
190	Enantioselective total synthesis of (-)-zampanolide, a potent microtubule-stabilizing agent. *Organic Letters*, **2011**, 13, 4108-11	6.2	64
189	Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. *Journal of Medicinal Chemistry*, **2011**, 54, 5890-901	8.3	30
188	Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands. *ACS Medicinal Chemistry Letters*, **2011**, 2, 298-302	4.3	26
187	Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. *Journal of Medicinal Chemistry*, **2011**, 54, 622-34	8.3	66
186	A stereoselective synthesis of (+)-herboxidiene/GEX1A. *Organic Letters*, **2011**, 13, 66-9	6.2	54
185	Cu(II)-catalyzed olefin migration and Prins cyclization: highly diastereoselective synthesis of substituted tetrahydropyrans. *Organic Letters*, **2011**, 13, 4328-31	6.2	36
184	Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1717-27	5.9	25
183	Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. *Journal of Virology*, **2011**, 85, 10079-89	6.6	34
182	Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3460-70	5.9	20
181	In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. *Journal of Virology*, **2010**, 84, 11961-9	6.6	73
180	The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS **2010**, 1-74		5
179	Capturing the essence of organic synthesis: from bioactive natural products to designed molecules in today's medicine. *Journal of Organic Chemistry*, **2010**, 75, 7967-89	4.2	23
178	Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity. *Journal of Organic Chemistry*, **2010**, 75, 2-10	4.2	45

177	Enantioselective syntheses of the proposed structures of cytotoxic macrolides iriomoteolide-1a and -1b. *Organic Letters*, **2010**, 12, 3120-3	6.2	16
176	The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [H]peloruside A. *Journal of Chemical Information and Modeling*, **2010**, 50, 2019-28	4.1	33
175	Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. *Journal of Medicinal Chemistry*, **2010**, 53, 4968-79	8.3	96
174	Highly diastereoselective synthesis of modified nucleosides via an asymmetric multicomponent reaction. *Chemical Communications*, **2010**, 46, 1218-20	5.8	11
173	Darunavir (Prezista): A HIV-1 Protease Inhibitor for Treatment of Multidrug-Resistant HIV **2010**, 29-44		6
172	Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. *ChemMedChem*, **2010**, 5, 1850-4	3.7	42
171	Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1241-6	2.9	14
170	Synthesis and biological evaluation of new jasplakinolide (jaspamide) analogs. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5104-7	2.9	12
169	Synthesis of Bioactive Natural Products by Asymmetric - and -Aldol Reactions. *Synthesis*, **2009**, 2009, 2992-3002	2.9	6
168	GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 997-1006	5.9	37
167	A symmetry-based concise formal synthesis of platencin, a novel lead against "superbugs". *Angewandte Chemie - International Edition*, **2009**, 48, 5372-5	16.4	29
166	Stereoselective synthesis of the C(1)-C(12) segment of iriomoteolide 1a: a very potent macrolide antitumor agent. *Tetrahedron Letters*, **2009**, 50, 1416-1418	2	23
165	Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. *Journal of Chemical Information and Modeling*, **2009**, 49, 2851-62	6.1	59
164	Asymmetric synthesis of anti-aldol segments via a nonaldol route: synthetic applications to statines and (-)-tetrahydrolipstatin. *Journal of Organic Chemistry*, **2009**, 74, 4508-18	4.2	43
163	Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2009**, 52, 3902-14	8.3	54
162	An asymmetric total synthesis of brevisamide. *Organic Letters*, **2009**, 11, 4164-7	6.2	37
161	Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. *Journal of Medicinal Chemistry*, **2009**, 52, 5228-40	8.3	86
160	A convergent synthesis of the proposed structure of antitumor depsipeptide stereocalpin A. *Organic Letters*, **2009**, 11, 1963-6	6.2	16

159	Total synthesis of (-)-platensimycin, a novel antibacterial agent. *Journal of Organic Chemistry*, **2009**, 74, 1163-70	4.2	69
158	Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. *Journal of Medicinal Chemistry*, **2009**, 52, 2163-76	8.3	41
157	Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. *Journal of Medicinal Chemistry*, **2009**, 52, 7689-705	8.3	37
156	P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. *Biological and Pharmaceutical Bulletin*, **2009**, 32, 1588-93	2.3	53
155	L-selectride-mediated highly diastereoselective asymmetric reductive aldol reaction: access to an important subunit for bioactive molecules. *Organic Letters*, **2008**, 10, 4811-4	6.2	26
154	Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. *Journal of Molecular Biology*, **2008**, 381, 102-15	6.5	69
153	Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease. *Journal of Molecular Biology*, **2008**, 384, 178-92	6.5	40
152	Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies. *Organic and Biomolecular Chemistry*, **2008**, 6, 3703-13	3.9	14
151	Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. *Journal of Medicinal Chemistry*, **2008**, 51, 6599-603	8.3	27
150	Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase. *Organic Letters*, **2008**, 10, 3907-9	6.2	84
149	Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. *Journal of Medicinal Chemistry*, **2008**, 51, 6021-33	8.3	36
148	Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. *Organic Letters*, **2008**, 10, 5135-8	6.2	12
147	Enantioselective total synthesis of peloruside A: a potent microtubule stabilizer. *Organic Letters*, **2008**, 10, 1001-4	6.2	62
146	A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16119-24	11.5	295
145	Memapsin 2 (beta-secretase) inhibitors: drug development. *Current Alzheimer Research*, **2008**, 5, 121-31	3	51
144	beta-Secretase as a therapeutic target for Alzheimer's disease. *Neurotherapeutics*, **2008**, 5, 399-408	6.4	158
143	Asymmetric multi-component reactions: convenient access to acyclic stereocenters and functionalized cyclopentenoids. *Tetrahedron: Asymmetry*, **2008**, 19, 1020-1026		10
142	Enantioselective Synthesis of Cyclopentyltetrahydrofuran (Cp-THF), an Important High-Affinity P2-Ligand for HIV-1 Protease Inhibitors. *Tetrahedron Letters*, **2008**, 49, 3409-3412	2	12

141	Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1031-6	2.9	81
140	Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5684-8	2.9	82
139	Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. *Accounts of Chemical Research*, **2008**, 41, 78-86	24.3	212
138	Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. *Advances in Pharmacology*, **2008**, 56, 169-97	5.7	42
137	Total synthesis of potent antitumor agent (-)-lasonolide A: a cycloaddition-based strategy. *Chemistry - an Asian Journal*, **2008**, 3, 1811-23	4.5	19
136	Enantioselective total synthesis of macrolide antitumor agent (-)-lasonolide A. *Organic Letters*, **2007**, 9, 1437-40	6.2	46
135	Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 7576-80	3.4	158
134	Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5876-80	2.9	76
133	Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. *Proteins: Structure, Function and Bioinformatics*, **2007**, 67, 232-42	4.2	74
132	Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. *Current Alzheimer Research*, **2007**, 4, 418-22	3	30
131	Enantioselective total synthesis of +-jasplakinolide. *Organic Letters*, **2007**, 9, 2425-7	6.2	44
130	Enantioselective synthesis of (-)-platensimycin oxatetracyclic core by using an intramolecular Diels-Alder reaction. *Organic Letters*, **2007**, 9, 4013-6	6.2	70
129	Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. *Journal of Medicinal Chemistry*, **2007**, 50, 4509-15	8.3	38
128	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. *Journal of Medicinal Chemistry*, **2007**, 50, 2399-407	8.3	85
127	A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2143-55	5.9	62
126	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. *Journal of Biological Chemistry*, **2007**, 282, 28709-28720	5.4	111
125	Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy. *Annual Reports in Medicinal Chemistry*, **2007**, 41, 183-196	1.6	27
124	Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance. *ChemMedChem*, **2006**, 1, 939-50	3.7	100

123	Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. *Molecular Pharmacology*, **2006**, 70, 1555-64	4.3	107
122	A Stereoselective Anti-Aldol Route to (3,3a,6a)-Hexahydrofuro[2,3-] furan-3-ol: A Key Ligand for a New Generation of HIV Protease Inhibitors. *Synthesis*, **2006**, 2006, 3015-3018	2.9	23
121	Asymmetric multicomponent reactions: diastereoselective synthesis of substituted pyrrolidines and prolines. *Organic Letters*, **2006**, 8, 4509-11	6.2	18
120	Total synthesis and revision of C6 stereochemistry of (+)-amphidinolide W. *Journal of Organic Chemistry*, **2006**, 71, 1085-93	4.2	55
119	Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. *Journal of Medicinal Chemistry*, **2006**, 49, 5252-61	8.3	131
118	Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. *Journal of Medicinal Chemistry*, **2006**, 49, 1379-87	8.3	119
117	Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. *Journal of the American Chemical Society*, **2006**, 128, 5310-1	16.4	57
116	Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. *Journal of Molecular Biology*, **2006**, 363, 161-73	6.5	117
115	Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1869-73	2.9	88
114	Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). *Biochemistry*, **2005**, 44, 105-12	3.2	66
113	TiCl4-promoted multicomponent reaction: a new entry to functionalized alpha-amino acids. *Organic Letters*, **2005**, 7, 7-10	6.2	29
112	Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 3576-85	8.3	52
111	Conformations of laulimalide in DMSO-d6. *Journal of the American Chemical Society*, **2005**, 127, 12838-46	16.4	35
110	Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 6767-71	8.3	98
109	Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 15-20	2.9	80
108	Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. *Molecular Pharmacology*, **2004**, 66, 113-21	4.3	69
107	In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. *Journal of Neurochemistry*, **2004**, 89, 1409-16	6	100
106	Asymmetric Syntheses of Potent Antitumor Macrolides Cryptophycin B and Arenastatin A. *European Journal of Organic Chemistry*, **2004**, 2004, 2131-2141	3.2	9

105	Stereoselective chloroacetate aldol reactions: syntheses of acetate aldol equivalents and darzens glycidic esters. *Organic Letters*, **2004**, 6, 2725-8	6.2	25
104	Total synthesis and structural revision of (+)-amphidinolide W. *Journal of the American Chemical Society*, **2004**, 126, 3704-5	16.4	65
103	Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). *Journal of Organic Chemistry*, **2004**, 69, 7822-9	4.2	126
102	High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. *Journal of Molecular Biology*, **2004**, 338, 341-52	6.5	182
101	Assignment of absolute stereochemistry and total synthesis of (-)-spongidepsin. *Organic Letters*, **2004**, 6, 2055-8	6.2	51
100	Chiral Bis(oxazolines). *Chemistry of Heterocyclic Compounds (New York, 1951): A Series of Monographs*, **2004**, 529-594		1
99	Synthetic studies of microtubule stabilizing agent peloruside A: an asymmetric synthesis of C-C segment. *Tetrahedron Letters*, **2003**, 44, 7659-7661	2	29
98	Asymmetric Total Synthesis of the Gastroprotective Microbial Agent AI-77-B. *European Journal of Organic Chemistry*, **2003**, 2003, 821-832	3.2	53
97	An enantioselective synthesis of the C-C segment of antitumor macrolide peloruside A. *Tetrahedron Letters*, **2003**, 44, 3967-3969	2	35
96	An enantioselective synthesis of the core unit of the non-nucleoside reverse transcriptase inhibitor taurospongin A. *Tetrahedron: Asymmetry*, **2003**, 14, 629-634		11
95	Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent. *Journal of Organic Chemistry*, **2003**, 68, 9823-6	4.2	52
94	Enantioselective total synthesis of (+)-amphidinolide t1. *Journal of the American Chemical Society*, **2003**, 125, 2374-5	16.4	84
93	Highly diastereoselective anti-aldol reactions utilizing the titanium enolate of cis-2-arylsulfonamido-1- acenaphthenyl propionate. *Organic Letters*, **2003**, 5, 1063-6	6.2	27
92	Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 3123-9	5.9	318
91	Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. *Antiviral Research*, **2002**, 54, 29-36	10.8	26
90	Chelation-controlled ester-derived titanium enolate aldol reaction: diastereoselective -aldols with mono- and bidentate aldehydes. *Tetrahedron Letters*, **2002**, 43, 5621-5624	2	14
89	Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1993-6	2.9	11
88	(-)-Doliculide, a new macrocyclic depsipeptide enhancer of actin assembly. *Journal of Biological Chemistry*, **2002**, 277, 32165-71	5.4	48

87	MULTICOMPONENT REACTIONS: SYNTHESIS OF SPIROCYCLIC TETRAHYDROPYRAN DERIVATIVES BY PRINS CYCLIZATION. *Heterocycles*, **2002**, 58, 659-666	0.8	16
86	Stereoselective Synthesis of the C-N Fragment of Griseoviridin. *Synthesis*, **2002**, 2002, 371-374	2.9	6
85	Beta-secretase as a therapeutic target for inhibitor drugs. *Current Medicinal Chemistry*, **2002**, 9, 1135-44	4.3	70
84	A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. *Journal of Virology*, **2002**, 76, 1349-58	6.6	125
83	Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. *Biochemistry* , **2002**, 41, 10963-7	3.2	184
82	The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. *Biochemistry*, **2002**, 41, 9109-15	3.2	214
81	Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity. *Biochemistry*, **2002**, 41, 8742-6	3.2	53
80	Chelation-controlled reduction: stereoselective formation of syn-1,3-diols and synthesis of compactin and mevinolin lactone. *Journal of Organic Chemistry*, **2002**, 67, 8783-8	4.2	31
79	Ester derived titanium enolate aldol reaction: chelation controlled diastereoselective synthesis of -aldols. *Tetrahedron Letters*, **2001**, 42, 1227-1231	2	16
78	A macrolactonization-based strategy to obtain microtuble-stabilizing agent (-)-laulimalide. *Tetrahedron Letters*, **2001**, 42, 3399-3401	2	24
77	Asymmetric hetero Diels-Alder route to quaternary carbon centers: synthesis of (-)-malyngolide. *Tetrahedron Letters*, **2001**, 42, 6231-6233	2	33
76	Total synthesis of microtubule-stabilizing agent (-)-laulimalide. *Journal of Organic Chemistry*, **2001**, 66, 8973-82	4.2	110
75	Tartaric Acid and Tartrates in the Synthesis of Bioactive Molecules. *Synthesis*, **2001**, 2001, 1281-1301	2.9	48
74	Syntheses of FDA Approved HIV Protease Inhibitors. *Synthesis*, **2001**, 2001, 2203-2229	2.9	91
73	Total synthesis of antitumor depsipeptide (-)-doliculide. *Organic Letters*, **2001**, 3, 635-8	6.2	51
72	Stereoselective synthesis of pseudopeptide microbial agent AI-77-B. *Organic Letters*, **2001**, 3, 2677-80	6.2	30
71	Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). *Journal of Medicinal Chemistry*, **2001**, 44, 2865-8	8.3	220
70	Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. *Biochemistry*, **2001**, 40, 10001-6	3.2	179

69	Synthetic studies of antitumor macrolide laulimalide: a stereoselective synthesis of the C-C segment. *Tetrahedron Letters*, **2000**, 41, 4705-4708	2	25
68	Stereoselective construction of quaternary carbon centers by three component coupling reactions. *Tetrahedron Letters*, **2000**, 41, 8425-8429	2	18
67	A stereoselective synthesis of (+)-boronolide. *Tetrahedron Letters*, **2000**, 41, 1003-1006	2	35
66	An enantioselective synthesis of the C-C segment of antitumor macrolide laulimalide. *Tetrahedron Letters*, **2000**, 41, 2319-2322	2	41
65	Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. *Science* , **2000**, 290, 150-3	33.3	668
64	Design of Potent Inhibitors for Human Brain Memapsin 2 (-Secretase). *Journal of the American Chemical Society*, **2000**, 122, 3522-3523	16.4	219
63	Total Synthesis of (-)-Laulimalide. *Journal of the American Chemical Society*, **2000**, 122, 11027-11028	16.4	88
62	A short synthesis of (+/-)-eburnamonine. *Journal of Organic Chemistry*, **2000**, 65, 5433-5	4.2	22
61	A convergent synthesis of (+)-cryptophycin B, a potent antitumor macrolide from Nostoc sp. cyanobacteria. *Organic Letters*, **2000**, 2, 1573-5	6.2	27
60	Asymmetric synthesis of (-)-tetrahydrolipstatin: an anti-aldol-based strategy. *Organic Letters*, **2000**, 2, 2405-7	6.2	48
59	TiCl Promoted Three Component Coupling Reaction : A New Method for the Synthesis of Functionalized Tetrahydrofurans and Tetrahydropyrans. *Tetrahedron Letters*, **1999**, 40, 1083-1086	2	31
58	TiC1 promoted three component coupling reaction: an efficient method for the substituted tetrahydropyrilidene acetates. *Tetrahedron Letters*, **1999**, 40, 4751-4754	2	17
57	Stereoselective Synthesis of 5--Carbamoylpolyoxamic Acid by [2,3]-Wittig-Still Rearrangement. *Tetrahedron*, **1999**, 55, 13369-13376	2.4	10
56	Synthetic studies of nucleoside antibiotics: a formal synthesis of (+)-sinefungin. *Journal of the Chemical Society Perkin Transactions 1*, **1999**, 1999, 3597-3601		7
55	Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir. *Chemical Communications*, **1999**, 1999, 1025-1026	5.8	20
54	Counterions of BINAP-Pt(II) and -Pd(II) complexes: novel catalysts for highly enantioselective Diels-Alder reaction. *Organic Letters*, **1999**, 1, 2157-9	6.2	57
53	A stereoselective synthesis of (-)-tetrahydrolipstatin. *Chemical Communications*, **1999**, 1999, 1743-1744	5.8	60
52	Total Synthesis of (+)-Polyoxin J. *Journal of Organic Chemistry*, **1999**, 64, 2789-2795	4.2	36

51	CHEMOSELECTIVE CATALYTIC HYDROGENATION OF ALKENES BY LINDLAR CATALYST. *Tetrahedron Letters*, **1998**, 39, 947-948	2	31
50	Convenient synthesis of novel macrocyclic urethanes: alkoxycarbonylation of amines and ring-closing metathesis strategy. *Tetrahedron Letters*, **1998**, 39, 1881-1884	2	17
49	RING-CLOSING METATHESIS STRATEGY TO UNSATURATED □- AND □LACTONES: SYNTHESIS OF HYDROXYETHYLENE ISOSTERE FOR PROTEASE INHIBITORS. *Tetrahedron Letters*, **1998**, 39, 4651-4654	2	111
48	Stereoselective Synthesis of Dihydroisocoumarin Moiety of Microbial Agent AI-77-B: a Diels-Alder Based Strategy. *Tetrahedron Letters*, **1998**, 39, 8803-8806	2	13
47	-Symmetric chiral bis(oxazoline)-metal complexes in catalytic asymmetric synthesis. *Tetrahedron: Asymmetry*, **1998**, 9, 1-45		681
46	Bis(oxazoline) derived cationic aqua complexes: highly effective catalysts for enantioselective Diels-Alder reactions. *Tetrahedron: Asymmetry*, **1998**, 9, 3687-3691		44
45	Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 687-90	2.9	139
44	Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 979-82	2.9	34
43	Stereoselective Synthesis of Protected Thymine Polyoxin C via [2,3]-Wittig-Still Rearrangement of Ribose-Derived Allylic Stannyl Ethers. *Journal of Organic Chemistry*, **1998**, 63, 6735-6738	4.2	15
42	Transition-State Mimetics for HIV Protease Inhibitors: Stereocontrolled Synthesis of Hydroxyethylene and Hydroxyethylamine Isosteres by Ester-Derived Titanium Enolate Syn and Anti-Aldol Reactions. *Journal of Organic Chemistry*, **1998**, 63, 6146-6152	4.2	54
41	-1-Aminoindan-2-ol in Asymmetric Syntheses. *Synthesis*, **1998**, 1998, 937-961	2.9	65
40	A Convenient Enzymatic Route to Optically Active l-Aminoindan-2-ol: Versatile Ligands for HIV-1 Protease Inhibitors and Asymmetric Syntheses. *Synthesis*, **1997**, 1997, 541-544	2.9	17
39	A Convergent, Enantioselective Total Synthesis of Streptogramin Antibiotic (-)-Madumycin II. *Journal of Organic Chemistry*, **1997**, 62, 7908-7909	4.2	39
38	Asymmetric Aldol Route to Hydroxyethylamine Isostere: Stereoselective Synthesis of the Core Unit of Saquinavir. *Journal of Organic Chemistry*, **1997**, 62, 6080-6082	4.2	32
37	Asymmetric alkylations and aldol reactions: (1,2)-2-aminocyclopentan-1-ol derived new chiral auxiliary. *Tetrahedron: Asymmetry*, **1997**, 8, 821-824		22
36	SYNTHETIC STUDIES OF ANTITUMOR MACROLIDE LAULIMALIDE: ENANTIOSELECTIVE SYNTHESIS OF THE C-C SEGMENT BY A CATALYTIC HETERO DIELS-ALDER STRATEGY. *Tetrahedron Letters*, **1997**, 38, 2427-2430	2	68
35	ESTER DERIVED TITANIUM ENOLATE ALDOL REACTION: HIGHLY DIASTEREOSELECTIVE SYNTHESIS OF SYN- AND ANTI-ALDOLS. *Tetrahedron Letters*, **1997**, 38, 7171-7174	2	37
34	Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. *Journal of Medicinal Chemistry*, **1996**, 39, 3278-90	8.3	89

33	Synthesis of Enantiomerically Pure Anti-Aldols: A Highly Stereoselective Ester-Derived Titanium Enolate Aldol Reaction. *Journal of the American Chemical Society*, **1996**, 118, 2527-2528	16.4	79
32	Total Synthesis of (+)-Sinefungin. *Journal of Organic Chemistry*, **1996**, 61, 6175-6182	4.2	60
31	A Convergent, Enantioselective Total Synthesis of Hapalosin: A Drug with Multidrug-Resistance Reversing Activity. *Angewandte Chemie International Edition in English*, **1996**, 35, 74-76		32
30	Conformationally Constrained Bis(oxazoline) Derived Chiral Catalyst : A Highly Effective Enantioselective Diels-Alder Reaction. *Tetrahedron Letters*, **1996**, 37, 3815-3818	2	81
29	ASYMMETRIC DIELS-ALDER REACTION : CIS-1-ARYLSULFONAMIDO-2-INDANOLS AS HIGHLY EFFECTIVE CHIRAL AUXILIARIES. *Tetrahedron: Asymmetry*, **1996**, 7, 375-378		19
28	ASYMMETRIC HETERO DIELS-ALDER REACTIONS OF DANISHEFSKY'S DIENE AND GLYOXYLATE ESTERS CATALYZED BY CHIRAL BISOXAZOLINE DERIVED CATALYSTS. *Tetrahedron: Asymmetry*, **1996**, 7, 2165-2168		63
27	CYCLIC SULFONE-3-CARBOXAMIDES AS NOVEL P-LIGANDS FOR Ro 31-8959 BASED HIV-1 PROTEASE INHIBITORS. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 83-88	2.9	32
26	SYNTHESIS AND OPTICAL RESOLUTION OF HIGH AFFINITY P-LIGANDS FOR HIV-1 PROTEASE INHIBITORS. *Tetrahedron Letters*, **1995**, 36, 505-508	2	74
25	Chiral Auxiliary Mediated Conjugate Reduction and Asymmetric Protonation: Synthesis of High Affinity Ligands for HIV Protease Inhibitors. *Journal of Organic Chemistry*, **1995**, 60, 6198-6201	4.2	12
24	HIGHLY STEREOSELECTIVE REDUCTION OF □-KETO ESTERS: UTILITY OF CIS-1-ARYLSULFONAMIDO-2-INDANOLS AS CHIRAL AUXILIARIES. *Tetrahedron Letters*, **1995**, 36, 6811-6814	2	24
23	The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1994**, 37, 1177-88	8.3	49
22	Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. *Journal of Medicinal Chemistry*, **1994**, 37, 2506-8	8.3	67
21	Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1993**, 36, 924-7	8.3	43
20	3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. *Journal of Medicinal Chemistry*, **1993**, 36, 292-4	8.3	83
19	Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. *Journal of Medicinal Chemistry*, **1993**, 36, 2300-10	8.3	66
18	Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic. *Journal of Organic Chemistry*, **1993**, 58, 1025-1029	4.2	38
17	Highly Enantioselective Aldol Reaction: Development of a New Chiral Auxiliary from -1-Amino-2-hydroxyindan. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 1673-1674		42
16	A Facile and Enantiospecific Synthesis of 2()- and 2()-[1'()-Azido-2-phenylethyl]oxirane. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 273-274		18

15	An Efficient Synthesis of Functionalized Urethanes from Azides. *Journal of the Chemical Society Chemical Communications*, **1992**, 1992, 1308-1310		10
14	INTRAMOLECULAR AND INTERMOLECULAR HYDROXYL REACTIVITY DIFFERENCES IN GINKGOLIDES A, B AND C AND THEIR CHEMICAL APPLICATIONS. *Tetrahedron Letters*, **1992**, 33, 6955-6958	2	21
13	N,N'-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines. *Tetrahedron Letters*, **1992**, 33, 2781-2784	2	85
12	Di(2-Pyridyl) Carbonate Promoted Alkoxycarbonylation of Amines: A Convenient Synthesis of Functionalized Carbamates. *Tetrahedron Letters*, **1991**, 32, 4251-4254	2	33
11	STEREOCONTROLLED SYNTHESIS OF HIV-l PROTEASE INHIBITORS WITH C-AXIS OF SYMMETRY. *Tetrahedron Letters*, **1991**, 32, 5729-5732	2	31
10	An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors. *Journal of Organic Chemistry*, **1991**, 56, 6500-6503	4.2	60
9	TOTAL SYNTHESIS OF GINKGOLIDE A. *Tetrahedron Letters*, **1988**, 29, 3205-3206	2	41
8	Total Synthesis of (±)-Ginkgolide B. *Journal of the American Chemical Society*, **1988**, 110, 649-651	16.4	156
7	Two-Step Synthesis of Furans by Mn(III)-Promoted Annulation of Enol Ethers. *Chemistry Letters*, **1987**, 16, 223-226	1.7	35
6	Mn(III)-PROMOTED ANNULATION OF ENOL ETHERS AND ESTERS TO FUSED OR SPIRO 2-CYCLOPENTENONES. *Tetrahedron Letters*, **1987**, 28, 175-178	2	45
5	Methods for Pyranoannulation: An Approach to a New Class of Polyethers. *Journal of Organic Chemistry*, **1985**, 50, 3017-3019	4.2	32
4	Diastereofacial Selection in Nitrile Oxide Cycloaddition Reactions. The Anti-Directing Effect of an Allylic Oxygen and Some New Results on the Ring Metalation of Isoxazolines. A Synthesis of (±)-Blastmycinone. *Journal of Organic Chemistry*, **1984**, 49, 2762-2772	4.2	92
3	The Isoxazoline Route to α-Methylene Lactones. *Tetrahedron Letters*, **1983**, 24, 2623-2626	2	27
2	Diastereoselection in Intermolecular Nitrile Oxide Cycloaddition (NOC) Reactions: Confirmation of the "Anti-Periplanar Effect" through a Simple Synthesis of 2-Deoxy-d-ribose. *Journal of the American Chemical Society*, **1982**, 104, 5788-5789	16.4	73
1	The Development of Titanium Enolate-based Aldol Reactions63-125		12